Posted by on March 31, 2017

CBD epilepsy drug gets orphan drug designation in the UK.  The announcement made on March 29th, 2017 was made by GW Pharmaceuticals which trades on the Nasdaq Stock Exchange as the symbol GWPH.  The European Medicine Agency granted GW Pharmaceuticals Orphan Drug status on 3/29/2017 for the product called Epidiolex® which is made by GW Pharmaceuticals and this is CBD drug.  CBD is an acronym for cannabanoid and cannabidiol is one of at least 113 active cannabinoids in cannabis.  The purpose of the investigational drug is to be a treatment of LGS.  LGS is the acronym for Lennox-Gastaut Syndrome.  LGS is difficult to treat.  LGS is a form of childhood onset epilepsy.

Breakthrough in Government Acceptance Allowing a CBD Epilepsy Drug to Treat Child-Hood Onset Epilepsy

Epidiolex® (cannabidiol)

   Epidiolex® (cannabidiol)

We are clearly progressing as a universal world-wide society with this announcement that Epidiolex® will be available to qualifying patients.  Seizures resulting from childhood epilepsy often occur in patients 2-8 years old.  It is common to see seizures occurring daily when diagnosed with Lennox-Gastaut Syndrome or LGS.  The theory is that CBD can calm or quiet the chemical and electrical functions in the brain that cause the seizure.  CBD does not have a psychotic effect on the brain.  It doesn’t get you high like THC can.  Therefore, the CBD is found to work with children.

CBD Epilepsy Drug Gets Orphan Drug Designation Helps Move the Cannabis Revolution in the Correct Direction

A CBD epilepsy drug gets orphan drug designation is allowing our society to show a breakthrough in government belief.  We are becoming more liberal worldwide in thought.  Being more sensitive to ideas to help people who are suffering is a monumental move that needs to continue worldwide.  Acceptance to treat individuals with Epilepsy by way of Epidiolex® or any future pharmaceutical that is developed is great step in the positive promotion of CBD and medical marijuana.  Cannabis is not bad and the belief that it is clearly is changing.  Kudos to GW Pharmaceuticals for getting this far in the medical cannabis revolution!